SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: rjk01 who wrote (1373)12/23/2004 10:49:50 PM
From: NeuroInvestment  Read Replies (1) of 1386
 
They reported only the first and most crucial analyses as they were completed. The rest of it--which would not pertain to any approvability, but will be interesting in terms of what went wrong--will be done by Feb.

I consider TBI DOA. CABG would need a Phase IIb and I don't know what endpoint acceptable to the FDA will tap the frontal functions that relate to the positive data in the Phase IIa.

Pharmos' best hope is to partner their CB-2 analgesia platform--the current upheaval in the painkiller sector makes this a more valuable commodity as it finishes preclinical tox.

I am not generally a big objector to management stock sales--they have lives too. But--at the moment I do not see how Pharmos' CEO--whose post-sales rebuff of questions is almost as awkward and poorly timed as the sales themselves--is going to ever regain credibility.

Harry
NeuroInvestment
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News